# IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)

Source: https://onco.cc/trials/nct05742607/  
OnCo record `nct05742607` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Durvalumab, Carboplatin, Paclitaxel / nab-paclitaxel in non-small-cell lung cancer and small-cell lung cancer, run by Innate Pharma, now recruiting.

## Summary

IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) is a phase 2 interventional study registered as NCT05742607 by Innate Pharma, with 70 participants planned, started 2023-06-23 and due to reach its primary completion in 2027-06. Interventions recorded: IPH5201 + durvalumab + standard chemotherapy. Conditions listed: Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05742607
- Phase: 2
- Setting: Official Title: A Phase II Multicenter, Open Label, Non-randomized Study of Neoadjuvant and Adjuvant Treatment With IPH5201 and Durvalumab in Patients With Resectable, Early-Stage (II to III) Non-Small Cell Lung CancEr (MATISSE)
- Sponsor: Innate Pharma
- Enrolled: 70

## Sources

- ClinicalTrials.gov NCT05742607: https://clinicaltrials.gov/study/NCT05742607

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)

---
JSON: https://onco.cc/api/v1/entities/nct05742607.json